Monographie - Tigecycline

Laatste update :
19/11/2024

Tigecycline

Molecuulstructuur

Merknamen in verschillende landen

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Eticina	Mexico
Grexyl	Mexico
Linicetil	Mexico
Mrsacin	Turkije
Tecygen	Chili
Tigecid	Turkije
Tigecilina	Argentinië, Chili, Ecuador
Tigecycline	Canada
Tigetop	Chili
Tizoxim	Argentinië
Tygacil	Argentinië, België, Canada, Chili, Colombia, Denemarken, Duitsland, Ecuador, Finland, Frankrijk, Griekenland, Groot Britannië, Hongarije, Ierland, IJsland, Italië, Japan, Luxemburg, Maleisië, Mexico, Nederland, nieuw Zeeland, Noorwegen, Oostenrijk, Peru, Polen, Portugal, Roemenië, Saudi-Arabië, Spanje, Turkije, USA, Venezuela, Verenigde Arabische Emiraten, Zweden, Zwitserland
Zomiprerin	Peru

Literatuur : Tigecycline

	type	publicatie
2262	Artikel	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	fabrikant	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Artikel	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	fabrikant	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	fabrikant	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	fabrikant	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	fabrikant	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Artikel	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Artikel	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Artikel	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Artikel	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Artikel	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales